AKT1 and non-small cell lung carcinoma: For instance, integrin β1 contributes to gefitinib resistance via PI3K/Akt signaling in NSCLC, and integrin β3 enhances erlotinib resistance in NSCLC through AXL/YAP pathway [32, 33].